We all know that hormone therapy (ADT2) stops the production of testosterone and blocks the little testosterone that might still be produced from entering into the prostate cancer cell to “feed” the cancer.
There have been a number of studies that have investigated and concluded that ADT not only stops testosterone, but also has anti-vascular effects in in prostate cancer tumors in animal models. There has not been any studies examining the vascular effects in human prostate cancer.
Researchers at the Marie Curie Research Wing, Mount Vernon Cancer Center, Northwood, England tested the hypothesis that like in the animal models, androgen deprivation causes significant reductions in human prostate tumor blood flow leading to the induction of hypoxia.
Twenty men were examined, using five multi-parameter magnetic resonance imaging scans: two scans before the commencement of ADT, one scan after 1 month of ADT, and two further scans after 3 months of therapy. Quantitative parametric maps of the prostate informing on relative blood flow (rBF), relative blood volume (rBV), vascular permeability (transfer constant